



Doc Code: AP.PRE.REQ

PTO/SB/33 (09-08)

Approved for use through 10/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PRE-APPEAL BRIEF REQUEST FOR REVIEW		Docket Number (Optional)	
<p>I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)]</p> <p>on <u>October 28, 2008</u></p> <p>Signature <u>Michele Hofherr</u></p> <p>Typed or printed name <u>Michele Hofherr</u></p>		Application Number	Filed
		09/980,649	June 4, 2002
		First Named Inventor	
		Pierre Belhumeur	
Art Unit		Examiner	
1651		Kim, Taeyoon	
<p>Applicant requests review of the final rejection in the above-identified application. No amendments are being filed with this request.</p> <p>This request is being filed with a notice of appeal.</p> <p>The review is requested for the reason(s) stated on the attached sheet(s). Note: No more than five (5) pages may be provided.</p>			
<p>I am the</p> <p><input type="checkbox"/> applicant/inventor.</p> <p><input type="checkbox"/> assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)</p> <p><input checked="" type="checkbox"/> attorney or agent of record. Registration number <u>39,839</u></p> <p><input type="checkbox"/> attorney or agent acting under 37 CFR 1.34. Registration number if acting under 37 CFR 1.34 _____</p>		<p><u>J. David Smith</u> Signature J. David Smith Typed or printed name</p> <p><u>201-487-5800</u> Telephone number</p> <p><u>October 28, 2008</u> Date</p>	
<p>NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.</p>			
<p><input checked="" type="checkbox"/> *Total of <u>3</u> forms are submitted.</p>			

This collection of information is required by 35 U.S.C. 132. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11, 1.14 and 41.6. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Pierre Belhumeur, *et al.* Art Unit: 1651
Serial Number: 09/980,649 Examiner: Kim, Taeyoon
Filing Date: June 4, 2002
For: BIOLOGICAL INDICATORS FOR VALIDATING A PRION
STERILIZATION PROCESS

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage in an envelope addressed to the COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on September 18, 2007.

Michele Hofherr
(Name of Person Depositing Mail)

Michele Hofherr 10-28-08
(Signature and Date)

PRE-APPEAL BRIEF REQUEST FOR REVIEW

Mail Stop BOX AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Please find enclosed herewith form PTO/SB/33, a Pre-Appeal Brief Request for Review. Please consider the reasons below for which the review is being requested. A Notice of Appeal is being filed concurrently.

REASONS:

1. The Examiner has failed to set forth a proper *prima facie* case of obviousness for any of the rejected claims 3 and 5-15.
2. Claims 3 and 5-15 are patentable under 35 USC 103(a) over Safar *et al.* in view of Coustou *et al.*, Glover *et al.* or Wickner *et al.*
3. Claim 9 is patentable under 35 USC 103(a) over Safar *et al.* in view of Coustou *et al.*, Glover *et al.* or Wickner *et al.* in further view of Feldman *et al.*

4. Claims 9, 10 and 13 are patentable under 35 USC 103(a) over Safar *et al.* in view of Coustou *et al.*, Glover *et al.* or Wickner *et al.* and further in view of Dresdner *et al.*

The Examiner declined a telephone interview with the inventors prior to the filing of this Pre-Appeal Brief Request for Review. In the Advisory Action issued on September 26, 2008, the Examiner acknowledges that in the Response to the Final Office Action, filed August 28, 2008, Applicants explained that the presently claimed invention is a method for evaluating the efficiency of a sterilization process whereas Safar *et al.* teach methods to study the thermal stability and conformational transitions of scrapie amyloid protein and their correlation with infectivity. The Examiner acknowledges that the current claims are drawn to a method of subjecting a prion protein to a degradation indicator and determining the level of degradation thereof. The Examiner alleges that Safar *et al.* teach the same method step since Safar *et al.* teach a method of subjecting a scrapie amyloid protein, which is a prion, to thermal exposure and evaluating the inactivity of the treated prion protein. Thus, the Examiner alleges that the process of Safar *et al.* is substantially similar, if not identical, to the presently claimed method. The Examiner also disagrees with Applicants' explanations that the yeast prion proteins of the current invention are not analogs of their mammalian counterpart, and that there is no teaching, motivation or suggestion to substitute the prion protein of Safar *et al.* with a yeast prion. The Examiner considers that since yeast proteins are recognized as "prion proteins" and known as analogs of the mammalian counterpart in the art, it would have been obvious to one of ordinary skill in the art to try the yeast prion proteins in the place of mammalian prion proteins.

1. The references when combined do not teach or suggest the presently claimed methods.

A. Regarding measuring degradation

Applicants submit that the references, when combined, do not produce the presently claimed methods. As such, the Examiner has failed to set forth a proper *prima facie* case of obviousness. Applicants respectfully reiterate that the goal of Safar *et al.* was to ***study the thermal stability and conformational transitions of scrapie amyloid protein and its correlation with infectivity***. To this end, Safar *et al.* submitted a scrapie amyloid protein to heat treatment and to chemical scrapie inactivators such as FA, SDS, additional α -helix-inducing fluorinated alcohols and TFA to measure their effect on the conformation of PrP27-30 and the ability to propagate,

replicate and cause disease. One of ordinary skill in the art would agree that analyzing the results of Safar *et al.*, particularly Figure 1 where the effect of heat and formic acid on PrP27-30 is visualized by silver staining and Western blot, reveals that Safar *et al.* only demonstrate a conformational transition of scrapie amyloid protein which they correlate with a reduction in infectivity. ***Safar et al. do not teach or suggest the degradation of a prion protein.*** On the contrary, the protein level visualized by silver staining and Western blot reported by Safar *et al.* is clearly not changed. (See, Fig. 1) Therefore, ***Safar et al. do not measure degradation.*** Rather, ***Safar et al. measure a conformational change*** which they correlate with the infectivity level of the prion. Safar *et al.* do not make a correlation between the infectivity level of the prion and its degradation.

The presently claimed method is for evaluating the efficiency of a sterilization process. Since some sterilization processes allow a significant degradation of prion proteins whereas other methods produce a weaker degradation, the method claimed in the present application allows the evaluation of the efficacy of different sterilization processes. ***The presently claimed methods measure***, when using for example ozone, a powerful sterilizing agent, ***the destruction or degradation of a yeast prion.*** Figure 4 of the present specification demonstrates that the prion protein is degraded as no band is observed in the “T” lane on the Western blot. Applicants respectfully submit that for a similar experimental protocol, following the reasoning of the Examiner, a degradation of the prion protein should be observed in Figure 1 of Safar *et al.* That is, degradation of the prion protein should normally be observed as a decrease in the intensity of bands observed in a Western blot. However, contrary to the Examiner’s position and contrary to what would be expected if degradation of the prion protein was in fact occurring, degradation is not demonstrated in Figure 1 of Safar *et al.*

B. Regarding replacing mammalian prion proteins with yeast prion proteins

The Examiner maintains that yeast prions are known as mammal prion analogs and thus it would have been obvious to replace the mammalian prion disclosed in Safar *et al.* by a yeast prion. Applicants refer to the Declaration under 37 C.F.R. 1.132 submitted on August 28, 2008 by Dr. Belhumeur, an inventor of the present invention, in order to evidence the contrary. Applicants submit that one of ordinary skill in the art would agree that there are ***significant differences between yeast prion proteins and mammalian prion proteins.*** Even though there

may be some belief among some scientists that yeast proteins are analogs of “prion proteins” and known as analogs of mammalian prions, there is still significant uncertainty regarding whether one of ordinary skill in the art could predict the utility of an invention based upon the teachings of Safar *et al.* using the proteins disclosed by Coustou *et al.*, Glover *et al.* or Wickner *et al.*

2. Claims 3 and 5-15 are patentable over Safar *et al.* in view of Coustou *et al.*, Glover *et al.* or Wickner *et al.*

Applicants respectfully submit that the methods of claims 3 and 5-15 are not obvious over Safar *et al.* in view of Coustou *et al.*, Glover *et al.* or Wickner *et al.* for the reasons set forth above. Additionally, the presently claimed methods provide significant advances over the prior art. The presently claimed methods may be adapted to industrial processes having a need to control the efficiency of a sterilization process. By Western Blot analysis, the present specification demonstrates that there is no residual yeast prion protein detectable after ozone treatment. (See, e.g. Table 1 of the instant specification) Ozone treatment goes beyond all the treatments described by Safar *et al.* as ozone is an extremely powerful oxidative process, able to break down chemical bonds. The mere fact of knowing from Safar *et al.* that heat or chemical treatment may have an effect on the conformation of a mammal prion protein is not sufficient to suggest to one of ordinary skill in the art a method of evaluating the efficiency of a sterilization process using proteins described by Coustou *et al.*, Glover *et al.*, or Wickner *et al.* Applicants respectfully suggest that alleging to the contrary constitutes impermissible hindsight.

3. Claim 9 is patentable over Safar *et al.* in view of Coustou *et al.*, Glover *et al.* or Wickner *et al.* in further view of Feldman *et al.*

For the reasons provided above, Applicants submit that the method of claim 9 is not obvious over Safar *et al.* in view of Coustou *et al.*, Glover *et al.* or Wickner *et al.* in further view of Feldman *et al.* The teachings of Safar *et al.* that heat or chemical treatment may affect the *conformation* of a mammal prion protein do not teach or suggest a method of evaluating the efficiency of a sterilization process (e.g. using oxidizing agents such as hydrogen as a form of low-temperature gas plasma as in Feldman *et al.*) using proteins described by Coustou *et al.*, Glover *et al.* or Wickner *et al.* As such, the references, when combined, do not produce the presently claimed methods.

4. Claims 9, 10 and 13 are patentable over Safar *et al.* in view of Coustou *et al.*, Glover *et al.* or Wickner *et al.* in further view of Dresdner *et al.*


Similarly, for the reasons provided above, Applicants submit that the methods of claims 9, 10 and 13 are not obvious over Safar *et al.* in view of Coustou *et al.*, Glover *et al.* or Wickner *et al.* in further view of Dresdner *et al.* The teachings of Safar *et al.* that heat or chemical treatment may affect the **conformation** of a mammal prion protein do not teach or suggest a method of evaluating the efficiency of a sterilization process (e.g. using ozone or sodium hydroxide as in Feldman *et al.*) using proteins described by Coustou *et al.*, Glover *et al.* or Wickner *et al.* As such, the references, when combined, do not produce the presently claimed methods.

5. Summary

For the reasons set forth above, Applicants submit that the claims are patentable over Safar *et al.*, Coustou *et al.*, Glover *et al.*, Wickner *et al.*, Feldman *et al.* and Dresdner *et al.* As such, Applicants respectfully submit that the 35 U.S.C. §103(a) rejections over the prior art are improper and request that the rejections be withdrawn. Applicants submit, therefore, that the claims are in condition for allowance, and prompt action in the form of a Notice of Allowance is earnestly solicited.

Respectfully submitted,

By:



J. David Smith,
Attorney for Applicants
Registration No. 39,839

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, NJ 07601
(201) 487-5800